Abstract: Hyaluronan (HA), a long-chain polysaccharide, is currently being evaluated as a potential therapeutic agent for a number of infl ammatory disorders. The effect of HA on infl ammation appears to be related to its molecular size, with larger polysaccharide chains having anti-infl ammatory activity and smaller ones having proinfl ammatory properties. This dichotomous behavior is particularly relevant to the work of our laboratory on an aerosolized preparation of HA to treat pulmonary emphysema. The breakdown of inhaled HA into smaller fragments could possibly induce an infl ammatory reaction in the lung that counteracts any benefi cial effect. Consequently, the proposed therapeutic use of HA will require development of treatment strategies aimed at minimizing its proinfl ammatory activity.
Introduction
In terms of understanding the pathogenesis of pulmonary emphysema, the use of papain to experimentally induce the disease represented an initial breakthrough (Gross et al 1964) . Originally intended as a possible treatment for interstitial pulmonary fi brosis, intratracheal instillment of papain instead produced emphysematous changes in the lung. This fi nding had added signifi cance because it came at a time when the relationship between alpha-1-antiproteinase defi ciency and pulmonary emphysema was just being recognized (Laurell and Eriksson 1963) . Both observations emphasized the importance of proteolysis as a cause of the disease. An imbalance between lung proteases and their inhibitors was hypothesized to be responsible for the airspace enlargement that characterizes pulmonary emphysema (Janoff 1985; Senior and Kuhn 1988) . It was proposed that excess elastase activity caused damage to the elastic fi ber network of the lung, leading to dilatation and rupture of alveoli, reduced gas-exchange, and eventual respiratory failure.
The proteinase-antiproteinase concept of pulmonary emphysema served to focus research on the role of elastases with the hope that inhibiting the activity of these enzymes would prevent lung injury. This treatment strategy assumed, however, that emphysema was caused by a single abnormality; namely, excess elastase activity. If the disease represented a more general response of the lung to a variety of insults, then enzyme inhibition might have only limited effi cacy.
With this in mind, our laboratory has studied the possible use of aerosolized hyaluronan (HA) to directly protect lung elastic fi bers from injury (Cantor et al 1998; Cantor et al 2000 Cantor et al , 2005 . HA, a long-chain polysaccharide, has been shown to preferentially bind to elastic fi bers, prevent elastolysis, and limit air-space enlargement in experimental models of emphysema induced by either porcine pancreatic elastase, human neutrophil elastase, or chronic exposure to cigarette smoke (Figure 1 ) (Cantor et al 1998 (Cantor et al , 2000 (Cantor et al , 2005 . Since elastic fi ber breakdown may be a fi nal common pathway in pulmonary emphysema, this form of treatment might be effective against a number of agents capable of causing the disease, including various oxidants present in air pollutants and cigarette smoke.
Special properties of HA
As a constituent of the extracellular matrix, HA acts to stabilize proteoglycans and also contributes to tissue growth and repair (Toole 1981; Heinegard and Paulsson 1984) . In particular, HA has been shown to be a critical component in amphibian limb regeneration, strongly infl uencing the initial stages of the process (Toole and Gross 1971) . One of the main functions of HA may be to reduce cellular cohesion, thereby facilitating the restructuring of tissues (Toole and Gross 1971) .
Production of HA is greatly elevated following experimental induction of both emphysema and interstitial fi brosis (Karlinsky 1982; LaFuma et al 1985; Bray et al 1991) . The increases observed in both diseases occur shortly after initiation of lung injury. In the case of interstitial fi brosis, damage to alveolar lining cells results in marked epithelial (type II cell) hyperplasia and subsequent lung remodeling, both of which are associated with HA synthesis (Cantor et al 1989) .
Since cell proliferation is not characteristic of pulmonary emphysema, the role of HA in this disease may depend more upon its interactions with other matrix components than its capacity to enhance tissue growth. Several studies suggest that HA and other glycosaminoglycans form a network which surrounds elastic fi bers (Baccarani-Contri et al 1990; Bray et al 1994) . Thus, the increased HA synthesis following emphysematous injury could prevent further damage to elastic fi bers and perhaps facilitate their repair.
More recently, HA has been found to play an important role in infl ammation. The infl ammatory activity of HA is related to its molecular weight, which can vary in tissues from thousands to millions of daltons. Low molecular weight fragments accumulate at sites of infl ammation, and are known to stimulate the production of a variety of cytokines (McKee et al 1996; Horton et al 1999; Mascarenhas et al 2004) . Conversely, high molecular weight HA fragments possess anti-infl ammatory properties, and may also promote repair of tissues (Moreland 2003; Noble and Jiang 2006) .
The proinfl ammatory potential of HA may be related to its affi nity for the CD44 receptor, an 85 kDa cell surface glycoprotein that is expressed by a variety of cell types. Interactions between endothelial cell HA and leukocyte CD44 receptors facilitate the extravasation of infl ammatory cells at sites of injury (Calkins et al 2001; Wang et al 2002; Kipnis et al 2003; Khan et al 2004) . Furthermore, the binding of HA to macrophage CD44 receptors induces transcription of proinfl ammatory genes (McKee et al 1996) .
The anti-infl ammatory activity of HA may be equally potent, but is less well understood. The mechanisms responsible for the mitigation of infl ammation by HA may depend not only on direct interaction with infl ammatory cells, but on the physical properties of the molecule itself. By virtue of its strongly anionic nature (due to negatively charged carboxyl groups), HA can retain relatively large amounts of water.
The ability of HA to expand its domain in a fl uid environment may have a number of consequences for tissue reactions. By creating a more viscous milieu, HA may impede the movement of cells and molecules through the extracellular matrix, thereby reducing the activity of leukocytes and their proinfl ammatory products. The consequences of this "physical barrier" effect of HA have been explored in our laboratory, where introduction of exogenous HA into the lung has been shown to slow the progression of lung injury in several animal models of pulmonary emphysema. Therapeutic applications of HA Aerosolized HA in experimental lung injury Pulmonary emphysema
The conceptual basis for using nebulized HA to treat pulmonary emphysema developed from a series of animal experiments designed to determine whether agents other than elastases were capable of inducing or enhancing pulmonary emphysema. A nonelastolytic enzyme, hyaluronidase, was shown to produce pulmonary airspace enlargement in hamsters when administered in conjunction with 60 percent oxygen (Cantor et al 1993) . Damage to elastic fi bers occurred only when both agents were given concomitantly, suggesting the possibility that hyaluronidase may facilitate the breakdown of these fi bers by making them more accessible to injury. This hypothesis was also tested in studies demonstrating that hyaluronidase enhances airspace enlargement in a wellestablished model of emphysema induced by intratracheal administration of elastase (Cantor et al 1995) .
Experiments were then undertaken to examine the effect of low molecular weight (150 kDa) HA itself on this model. Animals treated with aerosolized HA prior to instillation of elastase showed signifi cantly less airspace enlargement than controls treated with elastase alone (Cantor et al 1998 (Cantor et al , 2000 . The exogenous HA preferentially adhered to elastic fi bers, suggesting that it may protect these fi bers from enzymatic breakdown (Figure 2 ) (Cantor et al 1998 (Cantor et al , 2000 .
To determine if HA could actually prevent elastolysis, radiolabeled elastic fi bers, derived from rat pleural mesothelial cells, were used as a test substrate (Cantor et al 2000) . Coating the fi bers with HA signifi cantly decreased elastolysis induced by several different types of elastase, including human neutrophil elastase and human metalloproteinase.
In addition to protecting elastic fi bers from enzymatic breakdown, exogenously administered HA may also prevent air-space enlargement by increasing the water content of the extracellular matrix. Since the distensibility of elastic fi bers is dependent on interactions with water molecules, addition of HA may improve the mechanical properties of these fi bers, thereby preventing alveolar dilatation and rupture (Wasserman and Salemme 1990; Mariani et al 1997; Li et al 2001; Cantor et al 2004) .
Airway hyperreactivity
While our laboratory has concentrated on the use of HA to treat emphysematous lung injury, other investigators have demonstrated a benefi cial effect of this agent in animal models of airway hyperreactivity. When aerosolized HA was given to sheep, it signifi cantly reduced bonchoconstriction due to inhalation of either neutrophil or pancreatic elastase (Scuri et al 2001; Scuri and Abraham 2003) . In both cases, increasing the molecular weight of HA enhanced its effectiveness.
The mechanism of action of HA in preventing bronchoconstriction may involve an affi nity for tissue kallikrein, which could reduce kinin-mediated infl ammatory reactions in airway walls (Forteza et al 1999) . The increased ability of higher molecular weight HA to prevent bronchoconstriction might therefore refl ect a greater capacity for binding kallikrein.
More recently, aerosolized HA was shown to prevent exercise-induced bronchoconstriction in asthmatic patients (Petrigni and Allegra 2006) . Here again, the molecular weight of HA may play a critical role, as evidenced by the fact that Figure 2 HA is a long-chain polysaccharide composed of repeating disaccharide units of glucuronic acid and n-acetylglucosamine. When administered intratracheally, it binds to alveolar septal elastic fi bers and may prevent their degradation by elastases released from macrophages and neutrophils. another study using smaller-sized HA showed no protective effect (Kunz et al 2006) .
HA

Acute lung injury
Although previous studies from this laboratory indicated that administration of our preparation of HA was not associated with pulmonary infl ammation, other investigators have found that low-molecular weight HA may be proinfl ammatory (McKee et al 1996; Horton et al 1999; Mascarenhas 2004 ). This prompted us to determine if aerosolized HA could possibly enhance infl ammation in a more fulminant type of lung injury. Using an experimental model involving intratracheal instillation of endotoxin (Yasui et al 1995) , we tested the effects of HA on the acute infl ammatory response (Nadkarni et al 2005) . Animals were given aerosolized HA either immediately before or after administration of endotoxin, and studied over the next 24-hours. The results indicate that treatment with HA following endotoxin instillation enhanced lung infl ammation whereas pretreatment had the opposite effect.
This dichotomous response was refl ected by measurement of several parameters of lung injury, including histogical evidence of infl ammation, bronchoalveolar (BAL) cell content, TNFR1 expression on BAL macrophages, and lung apoptosis. Administration of aerosolized HA immediately before instillation of endotoxin signifi cantly reduced all of these infl ammatory markers compared to controls treated with endotoxin alone. Conversely, treatment with HA following endotoxin instillation signifi cantly increased all of the markers compared to endotoxin administration alone.
The proinflammatory effects of HA following endotoxin instillation may possibly involve alterations in the rate of leukocyte migration into the lung. By binding to CD44 receptors on the surface of neutrophils, the exogenous HA may reduce the interaction of these cells with the surrounding extracellular matrix and accelerate their infl ux into airspaces (Calkins et al 2001; Wang et al 2002; Kipnis et al 2003; Khan et al 2004) . Furthermore, increased expression of TNFR1 on macrophages may enhance TNF-alpha-induced secretion of enzymes that degrade HA into smaller fragments, thereby triggering the release of cytokines that amplify lung injury (McKee et al 1996) . Enhanced expression of TNFR1 may also account for the increased apoptosis seen in the lungs of animals post-treated with HA (Alikhani et al 2004) .
In contrast, pre-exposure to HA may decrease endotoxininduced infl ammation by limiting cell-cytokine interactions. For example, HA could bind to macrophage CD44 receptors, coat the cell surface, and block the attachment of TNF-alpha, thus preventing activation of various proinfl ammatory genes (Figure 3) .
Although the HA used in our experiments had a relatively low molecular weight, it nevertheless exhibited antiinfl ammatory activity when administered prior to endotoxin. This could possibly be explained by the self-aggregating properties of this molecule (Scott et al 1991) . Aerosolized HA deposited in the lung interstitium prior to endotoxin instillation may form larger complexes that exhibit the same anti-infl ammatory activity as high-molecular weight HA. When administered after endotoxin administration, however, HA might immediately be broken down and never form such complexes.
Maximizing the therapeutic potential of HA
The results of the experiments with endotoxin indicate that HA may be a double-edged sword with regard to its therapeutic effi cacy. In the absence of underlying infl ammation, HA may exert a benefi cial effect, as both an anti-infl ammatory agent and a protective barrier against the degradative activities of various infl ammatory products. Conversely, the presence of a pre-existing infl ammatory milieu has the potential to convert HA into a proinfl ammatory mediator and thereby counteract its therapeutic activity.
Further clinical testing of aerosolized HA should therefore involve frequent measurement of infl ammatory markers. These might include differential cell counts in bronchoalveolar lavage fl uid, sputum and plasma levels of proinfl ammatory cytokines, and markers of proteinase activity, such as plasma fi bronogen fragments (Stolk et al 2005) . The results of these studies could then be used to determine a dosing schedule for HA that minimizes the risk of an infl ammatory response.
Since HA can break down into smaller, proinfl ammatory fragments, increasing its initial molecular weight might also reduce the possibility of further lung injury. The use of 500 kDa HA, instead of a 150 kDa preparation, could limit the formation of proinfl ammatory, low-molecular weight fragments.
However, any increase in molecular weight would have to be weighed against possible changes in therapeutic effi cacy. Large molecules such as HA do not readily penetrate the alveolar epithelial barrier. Consequently, the dosage size and frequency of administration of HA will need to be carefully titrated to prevent its accumulation in alveolar spaces, where it can be broken down into smaller fragments. Measuring the clearance rate of HA from the lung could help determine the optimum dosing schedule.
Therapeutic applications of HA
The physical form in which HA is administered might also affect its therapeutic effi cacy. The use of a dry powder instead of a solution, or addition of a carrier molecule, might limit the breakdown of HA in the lung. Alternatively, it may be possible to modify the molecular structure of HA to reduce its proinfl ammatory potential while mainintaining its protective effects.
Conclusion
The use of nebulized HA as a potential treatment for pulmonary emphysema represents a different approach to treating disease -one that is directed toward the extracellular matrix rather than intracellular processes. The proposed mechanisms of action of HA discussed in this paper may have broad applicability to a number of other conditions involving injury to extracellular matrix components, including osteoarthritis (which is already being treated with exogenous HA), vascular aneurysms, and skin aging (Moreland 2003; Gandhi et al 1994; Fisher et al 1997) . However, exploiting the therapeutic potential of HA will require a greater understanding of the complex relationship between this molecule and the infl ammatory process. Such insight may not only advance the use of HA as a treatment for a variety of diseases, but also facilitate the development of a whole new class of agents designed to protect the extracellular matrix against the damaging effects of infl ammation.
